Chemoradiation for oesophageal cancer: the choice of treatment modality

Autor: Pauliina M. Kitti, Maria Faltinova, Juha Kauppi, Jari Räsänen, Tiina Saarto, Tiina Seppälä, Anu M. Anttonen
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Radiation Oncology, Vol 18, Iss 1, Pp 1-9 (2023)
Druh dokumentu: article
ISSN: 1748-717X
DOI: 10.1186/s13014-023-02290-9
Popis: Abstract Background Locally advanced oesophageal cancer can be treated with definitive chemoradiation (dCRT) or with neoadjuvant chemoradiation followed by surgery (nCRT + S), but treatment modality choice is not always clear. The aim of this study was to investigate the factors associated with the choice of treatment modality in locally advanced oesophageal cancer. Methods This was a retrospective cohort study of 149 patients treated with dCRT(n = 85) or nCRT + S (n = 64) for oesophageal cancer in Helsinki University Hospital in 2008–2018. Logistic regression was used to analyse factors associated with choice of treatment modality and to compare dosimetric factors with postoperative complications. Multivariate analyses identified factors associated with survival. Results Surgery was performed after chemoradiation as planned on 64/91 patients (70%). 28/64 had pathological complete response (44%). Probability of nCRT + S was higher in stages I-III versus IV (OR 3.62, 95% CI 1.53–8.53; P = .003), ECOG 0–1 versus 2 (OR 6.99, 95% CI 1.81–26.96; P = .005) or in the middle/lower vs upper oesophageal tumours (OR 5.61, 95% CI 1.83–17.16, P = .003). Probability for surgery was lower, if patient had lost > 10% of body weight (OR 0.46, 95% CI 0.21–0.98, P = 0.043). Patients in the nCRT + S group had significantly better median overall survival (mOS) and local control than the dCRT group (60 vs. 10 months, P
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje